EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In-Situ Forming Polyester Implants for Sustained Intravesical Oxybutynin Release

Michael Uwe Hartig, Jan Appelhaus, Marc Vollenbröker, Alf Lamprecht

Pharmaceutics · 23.10.2025 · 17 (11) · 1369

DOI: 10.3390/pharmaceutics17111369 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 23.10.2025. Verfasst von Michael Uwe Hartig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Farco-Pharma GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Neurogenic detrusor overactivity (NDO), caused by spinal cord injury or multiple sclerosis, is marked by involuntary bladder contractions and reduced urine volume. Current therapy requires frequent catheterization with oxybutynin hydrochloride. This work investigates a novel in situ forming implant (ISFI) with PLGA as a sustained-release formulation for the urinary bladder by quantifying drug release, polymer degradation, and solvent release in vitro. Methods/Results: Various formulation parameters were investigated, of which the drug load and PLGA termination were found to have the highest impact on drug release and polymer degradation. An increase in drug load from 1.5% to 7.5% for implants with the ester-terminated PLGA enhanced the degradation from 0% to around 20% after 7 d. Oxybutynin base catalyzed the polymer degradation, as implants with PLGA 502 and 15% drug load exhibited a degradation of 33% compared to 0% for 1.5% drug load. In the case of 1.5% drug load, the degradation could be increased by the use of an acid-terminated PLGA, compared to an ester-terminated. Conclusion: In summary, the feasibility of a biodegradable ISFI for NDO patients was shown, which could allow a single administration up to approx. one week, improving the quality of life for NDO patients. Additionally, this work provided insight to which formulation parameters can help to parallel drug release and polymer degradation.

Schlagwörter

Stichwörter der Autor:innen

PLGAbiodegradablein situ forming implantin vitrointravesical deliveryoxybutynin

Autor:innen und Institutionen

  • Department of Pharmaceutics, Institute of Pharmacy, University of Bonn, 53121 Bonn, Germany.
  • Farco Pharma GmbH, 50670 Cologne, Germany.

Förderung

  • Farco-Pharma GmbH

Zitieren

APA

Hartig, M. U., Appelhaus, J., Vollenbröker, M., & Lamprecht, A. (2025). In-Situ Forming Polyester Implants for Sustained Intravesical Oxybutynin Release. Pharmaceutics, 17(11), 1369. https://doi.org/10.3390/pharmaceutics17111369

Vancouver

Hartig MU, Appelhaus J, Vollenbröker M, Lamprecht A. In-Situ Forming Polyester Implants for Sustained Intravesical Oxybutynin Release. Pharmaceutics. 2025;17(11):1369. doi:10.3390/pharmaceutics17111369

BibTeX
@article{Hartig2025,
  author = {Hartig, Michael Uwe and Appelhaus, Jan and Vollenbröker, Marc and Lamprecht, Alf},
  title = {In-Situ Forming Polyester Implants for Sustained Intravesical Oxybutynin Release},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {11},
  pages = {1369},
  doi = {10.3390/pharmaceutics17111369}
}
Kostenlos starten →